Kura Oncology Inc. Common Stock (KURA)

FairStock Score: 21/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for durable profits bought at sensible prices, and Kura Oncology does not yet fit that mold. It is a clinical-stage oncology company with 260 employees and a commercial product, KOMZIFTI, but the filed figures show deep losses. In fiscal year 2025, the year ended 2025-12-31, revenue was $67.5 million and net loss was $278.7 million. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $20.9 million and net loss was $68.3 million, with diluted EPS of -$0.77. Revenue is rising from $53.9 million in fiscal year 2024, the year ended 2024-12-31, to $67.5 million in fiscal year 2025, but losses are far larger than sales. Trailing free cash flow is -$117.4 million, a FairStock free-cash-flow yield of -13.4% on the $874.5 million market cap. Financial health is weak by the numbers: debt-to-equity is 0.50, ROE is -167.71%, ROCE is -31.30%, Piotroski is 3/9, Altman Z is -1.63, and FairStock Score is 21/100. The Lynch category is none because the company lost money in each of the last four years. Any competitive moat would have to come from intellectual property, regulatory exclusivity, and clinical execution, not from current economics. At the 2026-10-13 close of $9.83, FairStock's P/B is 18.20 and P/E is -2.92. I see no margin of safety; this is a speculative pipeline bet, not a Graham-style bargain. Growth could be enormous if the drugs succeed, but I cannot underwrite that from the filed financials alone.

In plain English: Kura Oncology is a small cancer-drug company with a newly selling medicine and several experimental treatments. It is growing some revenue but still loses a lot of money and burns cash, so the business looks weak financially. At $9.83, the price looks expensive compared with those losses rather than clearly cheap.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer